• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Heat Biologics, OncoSec Medical collaborate on immunotherapy platforms

Heat Biologics, OncoSec Medical collaborate on immunotherapy platforms

February 19, 2015
CenterWatch Staff

Heat Biologics, a clinical stage biopharmaceutical company developing cancer immunotherapies based in Durham, N.C., and OncoSec Medical, a San Diego, Calif.-based company developing DNA-based intratumoral cancer immunotherapies, have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company.

Heat and OncoSec will jointly evaluate the preclinical efficacy of Heat's proprietary gp-96-Ig based ImPACT immunotherapy platform using OncoSec's core technology, ImmunoPulse, an investigational stage intratumoral DNA delivery platform.

Taylor Schreiber, M.D., Ph.D., heat's vice president of R&D, said, "This collaboration with OncoSec reflects our desire to expand Heat's ImPACT platform into DNA-based immunotherapies to stimulate immunity to both shared and private tumor antigens without introducing the complexities associated with personalized therapies.”

"In this collaboration we will evaluate the efficacy of Heat's proprietary DNA constructs with OncoSec's clinical stage electroporation platform," said Robert H. Pierce, M.D., OncoSec's chief scientific officer. "Heat's ImPACT platform is a unique approach that specifically activates tumor specific cytotoxic T-cells. We expect it will be effective with OncoSec's proprietary intratumoral delivery platform that has already shown promising clinical activity in both local and distant tumors in patients with metastatic melanoma.”

Heat and OncoSec are exploring this combination as part of their ongoing strategy to expand the application of their technologies to benefit cancer patients with unmet medical needs. Heat has two clinical stage programs based on the ImPACT platform, viagenpumatucel-L (HS-110) in a phase II clinical trial in patients with non-small cell lung cancer and vesigenurtacel-L (HS-410) in a phase II clinical trial in patients with non-muscle invasive bladder cancer. OncoSec's core platform, ImmunoPulse, which is based on the intratumoral delivery of DNA IL-12, currently is in phase II clinical trials, investigating the approach for treatment of metastatic melanoma, head and neck cancer, triple negative breast cancer and cutaneous T-cell lymphoma.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing